* * Search the Gazette
 
Harvard shieldHarvard University Gazette Harvard University Gazette
* Harvard News Office | Photo reprints | Previous issues | Contact us | Circulation
Current Issue:
March 02, 2006


News
News, events, features

Science/Research
Latest scientific findings

Profiles
The people behind the university

Community
Harvard and neighbor communities

Sports
Scores, highlights, upcoming games

On Campus
Newsmakers, notes, students, police log

Arts
Museums, concerts, theater

Calendar
Two-week listing of upcoming events

Subscribe  xml button
Gazette headlines delivered to your desktop

 

 


HARVARD GAZETTE ARCHIVES

HMS researchers find how gold fights arthritis

Sheds light on how medicinal metal function against rheumatoid arthritis and other autoimmune diseases

DeDecker
HMS postdoc Brian DeDecker is co-author of a study that reveals how 'we discovered a biochemical mechanism that may help explain how an old drug works.' (Staff photo Jon Chase/Harvard News Office)

Gold compounds have been used for the treatment of rheumatoid arthritis and other autoimmune diseases for more than 75 years, but, until now, how the metals work has been a mystery. Harvard Medical School (HMS) researchers report in the Feb. 27 issue of Nature Chemical Biology that special forms of gold, platinum, and other classes of medicinal metals work by stripping bacteria and virus particles from the grasp of a key immune system protein.

"We were searching for a new drug to treat autoimmune diseases," says Brian DeDecker, HMS postdoctoral student in the Department of Cell Biology and a study co-author. At the time of this work, DeDecker was in the HMS Institute of Chemistry and Cell Biology, which uses powerful chemical tools to illuminate complex biological processes and provide new leads for drug development. "But instead we discovered a biochemical mechanism that may help explain how an old drug works."

DeDecker and co-author Stephen De Wall undertook a large-scale search for new drugs that would suppress the function of an important component of the immune system, MHC class II proteins, which are associated with autoimmune diseases. MHC class II proteins normally hold pieces of invading bacteria and viruses on the surface of specialized antigen presentation cells. Presentation of these pieces alerts other specialized recognition cells of the immune system, called lymphocytes, which starts the normal immune response. Usually this response is limited to harmful bacteria and viruses, but sometimes this process goes awry and the immune system turns toward the body itself, causing autoimmune diseases such as juvenile diabetes, lupus, and rheumatoid arthritis.

During their search through thousands of compounds, the researchers found that the known cancer drug cisplatin, a drug containing the metal platinum, directly stripped foreign molecules from the MHC class II protein. From there, the researchers found that platinum was just one member of a class of metals, including a special form of gold, that all render MHC class II proteins inactive.

In subsequent experiments in cell culture, gold compounds were shown to render the immune system antigen presenting cells inactive, further strengthening this connection. These findings now give researchers a mechanism of gold drug action that can be tested and explored directly in diseased tissues.

In 1890, a German doctor named Robert Koch found that gold effectively killed the bacteria that caused tuberculosis. In the 1930s, based on a widely held but probably erroneous connection at the time between tuberculosis and rheumatoid arthritis, a French doctor, Jacques Forestier, developed the use of gold drugs for the treatment of rheumatoid arthritis. Gold drugs have been used since then as an effective treatment for this and other autoimmune diseases such as lupus, but treatment can take months for action and sometimes presents severe side effects, which have diminished use of these drugs in recent years.

With this new understanding of how these metals function, it may now be possible to develop a new generation of gold-based drugs for treating rheumatoid arthritis and other autoimmune diseases that are more effective with fewer side effects.







Copyright 2007 by the President and Fellows of Harvard College